Erlocent 150mg Tablet

Erlocent 150mg Tablet contains Erlotinib, a medication classified as a Kinase inhibitor. It is primarily used in adults with advanced non-small cell lung cancer, either as initial therapy or if the disease has not significantly responded to initial chemotherapy, specifically in cases where cancer cells have certain EGFR mutations.

Additionally, Erlocent 150mg Tablet is used in combination with gemcitabine to treat metastatic pancreatic cancer that has not responded to previous chemotherapy. Cancer occurs when cells in the body begin to grow uncontrollably and can spread to other areas.

Prior to treatment, your doctor may conduct certain blood tests. It is important to refrain from smoking during the course of Erlocent 150mg Tablet treatment, as smoking can reduce the effectiveness of the medication. Severe liver or kidney disease is a contraindication for using Erlocent 150mg Tablet.

Before taking Erlocent 150mg Tablet, inform your doctor if you have conditions such as diarrhea, glucuronidation disorder (e.g., Gilbert’s syndrome), a history of peptic ulcers or diverticular disease, use contact lenses, or have a history of eye problems such as severe dry eyes, corneal inflammation, or ulcers.

The use of Erlocent 150mg Tablet is generally not recommended during pregnancy or while breastfeeding unless it is considered absolutely necessary. It is not recommended for use in children and adolescents under 18 years of age.

Common side effects of Erlocent 150mg Tablet may include rash, infection, loss of appetite, weight loss, or depression. If any of these symptoms worsen, it is important to contact your doctor.